Other specific inclusion/exclusion criteria may apply. In order to determine eligibility,
further examination by the investigator is necessary.

Inclusion Criteria:

- Eligible patients must be at least 18 years of age with a diagnosis of multiple
myeloma including elevated M-blood/urine protein or a tumor that can be evaluated by
the doctor during the investigational drug's treatment.

- The patient's multiple myeloma must have gotten worse during/after previous
chemotherapy was given.

- Any side-effects from prior chemotherapy must have subsided

- Blood and urine tests must show adequate bone marrow, liver, and kidney function.

Exclusion Criteria:

Any of the following will exclude patients from study participation:

- indolent or smoldering myeloma or localized plasmacytoma

- hyperviscosity syndrome

- irradiation to 25% or more of bone marrow

- prior high dose chemotherapy with bone marrow or stem cell support

- current participation in other clinical trials

- pregnant or breast-feeding women

- known HIV-positive or AIDS-related illness

- patients planning to have radiation therapy or surgery that would interrupt study
therapy in the next 6 months.